Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06049225 · ClinicalTrials.gov registry record · NA
Medical Nutrition Therapy and Diabetes Self-Management Education for People With Disabilities
A NA study of Type 2 Diabetes and Physical Disability, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- NA
- Development phase
- 90
- Enrollment target
- 1
- Study location
NCT06049225: Completed NA study of Type 2 Diabetes and Physical Disability, sponsored by University of Alabama at Birmingham.
NCT06049225 is a NA study of Type 2 Diabetes and Physical Disability that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 90 participants, below the 3,923-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06049225, a NA study of Type 2 Diabetes and Physical Disability, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- NA
- Development phase
- 90 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this project is to develop, and pilot test an accessible and inclusive medical nutrition therapy and diabetes self-management education program for people with Type 2 Diabetes and physical disabilities.
Primary Outcome
Measured using the DQoL (Diabetes Quality of Life Measure) Questionnaire; Minimum score =1; maximum score = 5; Higher score represents worse outcome
Conditions Studied
Interventions
- BEHAVIORAL Attention Control
- BEHAVIORAL High-Tech
- BEHAVIORAL Low-Tech
Study Locations (1)
Alabama
- University of Alabama at Birmingham - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2024-06-01 |
| Est. Completion | 2025-09-01 |
| Phase | NA |
What the finished NCT06049225 record still lists
NCT06049225 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 3,923-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Type 2 Diabetes appearing as the primary indexed condition, and to 3 interventions - of which Attention Control is the first listed.
NCT06049225 reports a single indexed study location in Alabama.
Frequently Asked Questions
What is clinical trial NCT06049225 about?
NCT06049225 is a clinical study titled "Medical Nutrition Therapy and Diabetes Self-Management Education for People With Disabilities". The purpose of this project is to develop, and pilot test an accessible and inclusive medical nutrition therapy and diabetes self-management education program for people with Type 2 Diabetes and physical disabilities.
What is the current status of trial NCT06049225?
This trial is currently completed. It is a NA study. The enrollment target is 90 participants. The study started on 2024-06-01. Estimated completion is 2025-09-01.
What conditions does trial NCT06049225 study?
This clinical trial studies the following conditions: Type 2 Diabetes, Physical Disability.
What interventions are being tested in trial NCT06049225?
The interventions under investigation include: Attention Control (BEHAVIORAL), High-Tech (BEHAVIORAL), Low-Tech (BEHAVIORAL).
Who is sponsoring clinical trial NCT06049225?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06049225 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06049225's enrollment target sits among peer trials
90 168th of 327 higher than 158 of 327 other Type 2 Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Enhancing Telemedicine for T2D
RECRUITING · NA
-
Sleep and Glycemic Control in Type 2 Diabetes Adolescents
RECRUITING · NA
-
Enhancing Preventative Health Behaviors Among Emergency Department Hyperglycemic Patients
RECRUITING · NA
-
Ultrasound Effects on Glycemic Control in T2DM
RECRUITING · NA
-
A Randomized Double-Blinded and Placebo-Controlled Trial to Assess the Efficacy of Biophoton Therapy to Treat Type 2 Diabetes
RECRUITING · NA
-
High Fructose Diet, the Gut Microbiome, and Metabolic Health
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI